Spectral AI (NASDAQ:MDAI – Get Free Report) is one of 225 public companies in the “Surgical & medical instruments” industry, but how does it compare to its peers? We will compare Spectral AI to related businesses based on the strength of its analyst recommendations, profitability, earnings, risk, dividends, valuation and institutional ownership.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Spectral AI and its peers, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Spectral AI | 0 | 0 | 3 | 1 | 3.25 |
Spectral AI Competitors | 1667 | 4411 | 8446 | 250 | 2.49 |
Spectral AI currently has a consensus price target of $4.50, suggesting a potential upside of 214.69%. As a group, “Surgical & medical instruments” companies have a potential upside of 19.73%. Given Spectral AI’s stronger consensus rating and higher probable upside, analysts clearly believe Spectral AI is more favorable than its peers.
Earnings & Valuation
Gross Revenue | Net Income | Price/Earnings Ratio | |
Spectral AI | $18.06 million | -$20.85 million | -1.07 |
Spectral AI Competitors | $875.66 million | $48.15 million | -2.03 |
Spectral AI’s peers have higher revenue and earnings than Spectral AI. Spectral AI is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 47.6% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 56.7% of Spectral AI shares are owned by insiders. Comparatively, 15.9% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Spectral AI and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Spectral AI | -89.85% | N/A | -104.64% |
Spectral AI Competitors | -578.37% | -140.27% | -25.88% |
Volatility and Risk
Spectral AI has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Spectral AI’s peers have a beta of 0.52, meaning that their average share price is 48% less volatile than the S&P 500.
Summary
Spectral AI beats its peers on 10 of the 13 factors compared.
Spectral AI Company Profile
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.
Receive News & Ratings for Spectral AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral AI and related companies with MarketBeat.com's FREE daily email newsletter.